Date |
|
May 10, 2013 |
CEL-SCI Corporation Reports Second Quarter 2013 Financial Results |
Jun 26, 2013 |
CEL-SCI Corporation Announces Results of Annual Shareholders’ Meeting and Adjournment of Meeting to July 25, 2013 with Respect to Proposal Concerning Stock Option Plan |
Jul 19, 2013 |
CEL-SCI Reports on NYSE MKT Noncompliance Notice and Compliance Plan |
Jul 25, 2013 |
CEL-SCI and NIAID Publish Data Showing That CEL-SCI’s LEAPS Technology Halted Progression of Lethal Influenza in Three Different Influenza Virus Strains, Including a Drug-Resistant and a 2009 Pandemic Flu Strain |
Aug 9, 2013 |
CEL-SCI Corporation Reports Third Quarter 2013 Financial Results |
Sep 3, 2013 |
CEL-SCI Announces That NYSE MKT Approves Plan |
Sep 9, 2013 |
CEL-SCI Corporation's Manufacturing and Laboratory Operations Deemed Compliant with GMP Requirements Following Audit by European Union Qualified Person for a Second Time |
Sep 20, 2013 |
CEL-SCI Corporation Announces 1-for-10 Reverse Stock Split |
Oct 4, 2013 |
CEL-SCI Announces That NYSE MKT Granted an Extension to Regain Compliance |
Oct 7, 2013 |
CEL-SCI Announces Cooperative Research and Development Agreement (CRADA) for Multikine with US Navy |